Sequencing trastuzumab deruxtecan and sacituzumab govitecan in metastatic breast cancer: a systematic review and meta-analysis.

What was studied

This review compared the order of use of trastuzumab deruxtecan and sacituzumab govitecan. Both are used for metastatic breast cancer. The team asked which order works better for the later drug. They included 17 retrospective studies.

What they found

The main pool had 292 patients who took SG then T-DXd. It had 286 patients who took the reverse order. Time without progression on the later drug was 3.3 months after SG then T-DXd. It was 2.8 months after T-DXd then SG. The pooled hazard ratio was 1.54, and its range included no difference.

What it means for patients

The authors say point estimates favoured SG then T-DXd. They say current data do not prove that either order is better. They call for prospective studies split by tumor subtype.

Why it is not certain yet

The authors rate the certainty of the evidence as very low. All the studies were retrospective. The authors say tumor subtype likely confounds the results. The studies also differed in their findings.

Source

Sequencing trastuzumab deruxtecan and sacituzumab govitecan in metastatic breast cancer: a systematic review and meta-analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.